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 Exercise has been shown to be effective in improving function and quality of life (QoL) 1 and is recommend-
ed by the American College of Sports Medicine 2 and the 
American Cancer Society 3 for many cancer survivors. How-
ever, the evidence of effectiveness is not as consistent in 
lung cancer survivors. 4 This inconsistency may be related to 
characteristics unique to lung compared with other cancer 
survivors, including differences in age, comorbidities, and 
the effects of lung cancer and its treatment on exercise ca-
pacity (EC). Many patients with lung cancer are elderly and 
have major comorbidities that include chronic obstructive 
pulmonary disease (COPD) and heart failure that may limit 
EC. 5 Also, curative-intent therapy of lung cancer necessi-
tates the removal and/or destruction of lung tissue, which 
may further exacerbate symptoms and impede cardiopul-
monary function and EC in some patients. 
 Symptom burden may limit exercise in lung cancer sur-
vivors. Following lung cancer resection surgery, dyspnea 
worsens 6 partly due to a loss of 10-15% of lung function. 7 
Clinically signifi cant dyspnea has been shown to be preva-
lent in  > 50% of lung cancer survivors. 8-11 As a result, lung 
cancer survivors may avoid exercise to prevent dyspnea. 
In time, this avoidance can lead to a downward spiral of 
health related to physical function, symptom burden, and 
QoL (see Supplemental Digital Content 1, available at: 
 http://links.lww.com/JCRP/A132 ), all of which are im-
portant survivorship issues in lung cancer. 12 Therefore, the 
characterization of dyspnea in lung cancer survivors may 
provide important insights into factors associated with dys-
pnea and may facilitate interventions to improve exercise, 
function, and QoL in these patients. 
 The purpose of this project was to identify clinical pre-
dictors or determinants of dyspnea in lung cancer survivors 
following curative-intent therapy and analyze the relation-
ship between dyspnea and functional EC. It is believed that 
optimization of underlying comorbidities including cardio-
pulmonary disease may be important in improving exercise, 
function, and QoL in these patients. 
 METHODS 
 In a previous cross-sectional study to assess function-
al EC and patient-reported outcomes in lung cancer sur-
vivors following curative-intent therapy, exploratory 
patient-reported outcomes assessments identifi ed abnor-
mally high dyspnea in  ≈ 60% of participants 13 as assessed 
by the European Organization for the Research and Treat-
ment of Cancer Quality of Life Questionnaire Lung Cancer 
Module 13 (LC13). 14 In this study, additional participants 
were enrolled to identify clinical predictors or determinants 
of dyspnea and explore its relationship with functional EC. 
Guideline recommendations for Strengthening the Report-
ing of Observational studies in Epidemiology were used 
to report fi ndings. 15 The VA San Diego Healthcare System 
(VASDHS) Institutional Review Board approved this pro-
tocol (#H150158). 
 At the VASDHS, all patients diagnosed with primary or 
progressive/recurrent lung cancer are presented to a weekly 
multidisciplinary chest tumor board for management 
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 Purpose:  Dyspnea  is highly prevalent in lung cancer survivors 
following curative-intent therapy. We aimed to identify clinical 
predictors or determinants of dyspnea and characterize its rela-
tionship with functional exercise capacity (EC). 
 Methods:  In an analysis of data from a cross-sectional study of 
lung cancer survivors at the VA San Diego Healthcare System who 
completed curative-intent therapy for stage I-IIIA disease  ≥ 1 mo 
previously, we tested a thorough list of comorbidities, lung func-
tion, and lung cancer characteristics. We assessed dyspnea using 
the European Organization for the Research and Treatment of 
Cancer Quality of Life Questionnaire Lung Cancer Module 13 
(LC13) and functional EC using the 6-minute walk. We replicated 
results with the University of California San Diego Shortness of 
Breath Questionnaire. 
 Results:  In 75 participants at a median of 12 mo since treat-
ment completion, the mean  ± SD LC13-Dyspnea score was 
35.3  ± 26.2; 60% had abnormally high dyspnea. In multivari-
able linear regression analyses, signifi cant clinical predictors or 
determinants of dyspnea were ( β [95% CI]) psychiatric illness 
( − 20.8 [ − 32.4 to  − 9.09]), heart failure with reduced ejec-
tion fraction ( − 15.5 [ − 28.0 to  − 2.97]), and forced expirato-
ry volume in the fi rst second of expiration ( − 0.28 [ − 0.49 to 
 − 0.06]). Dyspnea was an independent predictor of functional 
EC ( − 1.54 [ − 2.43 to  − 0.64]). These results were similar with 
the University of California San Diego Shortness of Breath 
Questionnaire. 
 Conclusion:  We identifi ed clinical predictors or determinants 
of dyspnea that have pathophysiological bases. Dyspnea was 
independently associated with functional EC. These results have 
implications in efforts to reduce dyspnea and improve exercise 
behavior and functional EC in lung cancer survivors following 
curative-intent therapy. 
 Key Words:  exercise •  lung neoplasms •  patient-reported out-
come measures •  survivorship •  symptom assessment 
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planning. From a list of consecutive patients presented at 
the VASDHS chest tumor board, kept to ensure quality 
clinical care, potentially eligible patients were identifi ed. 
Between August 2016 and April 2018, consecutive patients 
were recruited by informational letters mailed to those 
whose lung cancer was diagnosed and/or managed at the 
VASDHS since October 2010. Follow-up occurred with a 
maximum of 3 telephone calls 1 wk later to gauge interests 
and written informed consent was obtained from all partic-
ipants. Previously, 87% of all eligible patients were enrolled 
using this recruitment method. 13 
 This study included lung cancer survivors with pathologic 
and presumed lung cancer diagnoses (ie, those with lung nod-
ules deemed by the chest tumor board to have high pre-test 
probability for lung cancer but at high risk for severe com-
plications from tissue biopsy) who completed lung cancer 
resection surgery, defi nitive radiation, or concurrent chemo-
radiation for stage I-IIIA disease  ≥ 1 mo previously. The 
study excluded patients who had progressive/recurrent lung 
cancer or were unable to follow directions and/or physically 
perform functional EC evaluation: severe dementia, bilateral 
below-knee amputation, or quadriplegia, and active systemic 
treatment for other cancers. A thorough list of clinical vari-
ables related to lung cancer and/or cardiopulmonary health 
were collected using data from the electronic health records. 
These included age, sex, body mass index, tobacco exposure, 
comorbidities (including COPD, heart failure with reduced 
ejection fraction [HFrEF], psychiatric illness), lung function 
(forced expiratory volume in the fi rst second of expiration 
[FEV 1 ], diffusion of the lung for carbon monoxide, total 
lung capacity), and echocardiographic fi ndings where avail-
able. Chronic obstructive pulmonary disease was defi ned as 
clinical documentation of COPD by a pulmonologist and/or 
postbronchodilator FEV 1 /forced vital capacity  < 0.7 on spi-
rometry, HFrEF as clinical documentation of systolic heart 
failure or echocardiographic ejection fraction  ≤ 50%, and 
psychiatric illness as anxiety, depression, or post-traumatic 
stress disorder documented by a psychiatrist and/or active 
prescriptions of anxiolytics or antidepressants. Lung cancer 
characteristics included clinical stage and treatment modal-
ity. Time since treatment completion was also included to 
assess the possible effects of treatment or recovery on out-
comes. All data were collected by a board-certifi ed physician 
with subspecialty training in pulmonology (D.H.). 
 DYSPNEA ASSESSMENTS 
 Dyspnea was assessed using the LC13 14 and the University 
of California San Diego Shortness of Breath Questionnaire 
(SOBQ). 16 The LC13-Dyspnea score was used for primary anal-
yses due to previous validation in the lung cancer population. 14 
The LC13 is a 13-item questionnaire designed to assess lung 
cancer–associated symptoms (cough, dyspnea, hemoptysis, and 
pain) and chemo- and radiotherapy side effects (dysphagia, hair 
loss, neuropathy, sore mouth); dyspnea is assessed by 3 items 
on perceived shortness of breath at rest, when walking, and 
climbing stairs, scored as a mean of the component items with 
raw score range of 0 to 100. 14 Abnormally high dyspnea was 
defi ned as LC13-Dyspnea scores greater than mean reference 
value. 17 The SOBQ was used to replicate fi ndings. The SOBQ is 
a 24-item questionnaire designed to assess self-reported short-
ness of breath with a variety of activities of daily living in pa-
tients with chronic lung disease 16 that has previously been used 
in lung cancer survivors 13 , 18 ; responses are summed to a score 
range of 0 to 120. 16 In both the L13 and SOBQ questionnaires, 
higher scores indicate a higher level of perceived dyspnea. All 
questionnaire assessments were performed at the same time on 
printed forms without any modifi cations and prior to function-
al EC testing. 
 FUNCTIONAL EC 
 The primary outcome was functional EC as assessed by the 
6-minute walk test, performed according to the standard 
protocol recommended by the American Thoracic Society 
Pulmonary Function Standards Committee. 19 In lung can-
cer survivors, the 6-min walk test distance (6MWD) has 
been validated against the gold standard of cardiopulmo-
nary fi tness (maximal EC, maximal or peak oxygen uptake) 
(concurrent validity), 20 shown to decrease with treatment 
(responsiveness), 21 shown to be low compared with gener-
al age-, sex-, height-, and weight-matched adults (discrim-
inant validity), 13 and was independently associated with 
cancer-specifi c QoL (predictive validity). 13 
 STATISTICAL ANALYSES 
 Descriptive statistics were summarized as appropriate; both 
L13-Dyspnea and SOBQ scores were analyzed as continu-
ous variables. Univariable (UVA) and multivariable (MVA) 
linear regressions were used to analyze the relationship 
between all collected clinical characteristics and identify 
predictors or determinants of dyspnea and analyze the rela-
tionship between dyspnea and functional EC. 
 For MVAs, stepwise, backward selection modeling was 
used, starting with all variables with  P  < .10 in UVAs; those 
with the largest  P values were sequentially eliminated from 
the models until all remaining variables were associated 
with the dependent variable (dyspnea or functional EC) at 
 P  < .10. Results were interpreted using regression coeffi -
cients ( β ), 95% CI, and coeffi cients of determination ( R 2 
and partial  R 2 ), and statistical signifi cance was defi ned as  P 
 < .05 in 2-tailed tests. All data were managed with RED-
Cap electronic data capture tools 22 hosted at the local insti-
tution and analyzed as available without imputation using 
IBM SPSS Statistics software versions 25 and 26. 
 RESULTS 
 This study enrolled 75 lung cancer survivors at a median 
of 12 mo since completing curative-intent therapy. Their 
baseline clinical characteristics are described in  Table 1 . 
Most were white males with a history of tobacco use, con-
comitant COPD, and underwent either lung cancer resec-
tion surgery or defi nitive radioablation for the treatment of 
stage I non–small cell lung cancer (NSCLC). 
 DYSPNEA AND FUNCTIONAL EC 
 All participants completed dyspnea and 6MWD assess-
ments. The LC13-Dyspnea and SOBQ scores were 35.3  ± 
26.2 and 34.8  ± 25.6, respectively. These scores correlat-
ed very well ( r  = 0.84,  P  < .001) (see Supplemental Dig-
ital Content 2, available at:  http://links.lww.com/JCRP/
A133 ). Forty-fi ve participants (60%) had abnormally high 
dyspnea, defi ned as LC13-Dyspnea raw score greater than 
mean reference value for patients with lung cancer (29.5). 17 
The 6MWD was 347.9  ± 124.2 m (67% of predicted val-
ues in healthy adults 23 ) ( Table 1 ). 
 PREDICTORS OR DETERMINANTS OF DYSPNEA 
 Clinical variables borderline signifi cantly ( P  < .10) asso-
ciated with dyspnea are shown in Supplemental Digital 
Content 3, available at:  http://links.lww.com/JCRP/A134 . In 
MVAs ( β [95% CI]), psychiatric illness ( − 20.8 [ − 32.4 to 
 − 9.09] for  No/Yes ), HFrEF ( − 15.5 [ − 28.0 to  − 2.97] for  No/
Yes ), and FEV 1 ( − 0.28 [ − 0.49 to  − 0.06] for each  % predict-
ed ) were signifi cant independent predictors or determinants of 
dyspnea as determined from the LC13. Time since treatment 
completion was not associated with dyspnea. Results were 
similar with the SOBQ ( Table 2 ;  Figure 1A and B). 
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 Table 1 
 Participant Characteristics 
Participant Characteristic (N  = 75, VASDHS, 
2016-2018) Value 
Age, yr 70.7  ± 8.4 
Male sex 71 (95) 
Race 
 Asian 4 (5) 
 Black 2 (3) 
 Hispanic 1 (1) 
 White 68 (91) 
BMI, kg/m 2 26.8  ± 4.8 
Smoking history 
 Current 24 (32) 
 Former 44 (59) 
 Never 7 (9) 
Pack yr 52.0  ± 31.7 
Comorbidities 
 Hypertension 61 (81) 
 Hyperlipidemia 60 (80) 
 Diabetes mellitus 21 (28) 
 Atrial fibrillation/flutter 18 (24) 
 CAD 26 (35) 
 COPD 56 (75) 
 HFrEF a 18 (24) 
 Diastolic dysfunction b 37 (79) 
 OSA 17 (23) 
 Anxiety/depression/PTSD 22 (29) 
 Other cancer 30 (40) 
Pulmonary function c 
 FEV 1 /FVC, % 59.6  ± 14.6 
 FEV 1 , % predicted 70.7  ± 25.0 
 TLC, % predicted b 110.8  ± 21.5 
 DL CO , % predicted 78.5  ± 25.4 
Lung function abnormality d 
 Obstructive d 57 (76) 
 Hyperinflated d 18 (28) 
 DL CO limited d 41 (55) 
Lung cancer 
Clinical stage 
 IA 50 (67) 
 IB 9 (12) 
 IIA 3 (4) 
 IIB 11 (15) 
 IIIA 2 (3) 
Histology 
 Adenocarcinoma 37 (49) 
 Squamous cell carcinoma 18 (24) 
 Presumed 15 (20) 
Primary treatment 
 Surgical resection 37 (49) 
 Definitive radioablation 27 (36) 
 Chemoradiation 11 (15) 
Months since treatment 
 Median 12.2 
 Interquartile range 1.8, 35.6 
Dyspnea scores 
 LC13-Dyspnea, point 35.3  ± 26.2 
 SOBQ, point 34.8  ± 25.6 
(continues)
 Table 1 
 Participant Characteristics (Continued) 
Participant Characteristic (N  = 75, VASDHS, 
2016-2018) Value 
Functional EC (6MWD), m  347.9  ± 124.2 
 Abbreviations: BMI, body mass index; CAD, coronary artery disease; COPD, chronic 
obstructive pulmonary disease; DL CO , diffusion capacity of the lung for carbon monoxide; 
EC, exercise capacity; FEV 1 , forced expiratory volume in the first second of expiration; FVC, 
forced vital capacity; HFrEF, heart failure with reduced ejection fraction; LC13, European 
Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung 
Cancer Module 13; OSA, obstructive sleep apnea; PTSD, post-traumatic stress disorder; 
6MWD, 6-minute walk distance; SOBQ, University of California San Diego Shortness of 
Breath Questionnaire; TLC, total lung capacity; VASDHS, VA San Diego Healthcare System. 
Data reported as mean ± SD or n (%). 
 a Defined as ejection fraction  ≤ 50% or clinical documentation of systolic heart failure. 
 b Data available in 64 participants (85%) for TLC % predicted and 47 (63%) for diastolic dysfunction. 
 c Data obtained after completion of lung cancer treatment in 32 (43%) participants. 
 d Defined as FEV 1 /FVC  < 70% for obstructive defect, TLC % predicted  > 120 for 
hyperinflation, and DL CO % predicted  < 80 for DL CO limitation. 
www.jcrpjournal.com Dyspnea in Veteran Early-Stage Lung Cancer Survivors     3
 Dyspnea Is an Independent Predictor of Functional EC 
 Results of UVAs to identify predictors of functional EC are 
shown in  Table 3 . In MVAs starting with all baseline clinical 
characteristics borderline signifi cantly associated with func-
tional EC, dyspnea was found to be an independent pre-
dictor of functional EC ( − 1.54 [ − 2.43 to  − 0.64] for each 
 point ) ( Table 4 ;  Figure 2A ). These results were replicated by 
the SOBQ ( − 1.70 [ − 2.62 to  − 0.78]) ( Table 4 ;  Figure 2B ). 
 DISCUSSION 
 In an analysis of data from a cross-sectional study of veter-
an lung cancer survivors following curative-intent therapy, 
this study found abnormally high dyspnea in most patients 
and identifi ed 3 important clinical predictors or determi-
nants of dyspnea: psychiatric illness (anxiety/depression/
post-traumatic stress disorder), HFrEF, and physiological 
measure of obstructive ventilatory defect (FEV 1 ). In addi-
tion, dyspnea was an independent predictor of functional 
EC and accounted for 14-16% of its variance. These results 
highlight the importance of dyspnea in early-stage lung 
cancer survivorship and have implications for interventions 
aimed at improving exercise, function, and QoL in these 
patients. 
 The Institute of Medicine emphasizes the fundamental 
importance of care in the post-treatment phase of cancer 
survivorship, including supportive services to promote 
health and reduce long-term and late treatment effects. 24 
Exercise is recommended by the American College of 
Sports Medicine 2 and the American Cancer Society 3 for 
many cancer survivors to promote health and reduce func-
tional and QoL impairments. These recommendations are 
based on evidence of effectiveness in breast, prostate, and 
colon cancer survivors 25-27 ; however, this evidence is not 
as consistent in lung cancer survivors. 4 Recent systematic 
reviews of exercise interventions in lung cancer survivors 
suggest that while exercise training as part of rehabilitation 
programs can improve functional EC and QoL following 
curative-intent therapy, 28-31 concerns for selection bias and 
inadequate sample size exist. 28 , 29 , 32 Moreover, a recent sys-
tematic review identifi ed numerous patient-related barriers 
to regular exercise in lung cancer survivors. 33 These include 
physical capacity, symptoms, comorbidities, previous sed-
entary lifestyle, and psychological infl uences. 33 
 Lung cancer survivors are different from other cancer 
populations due to a higher median age at diagnosis, life-
time exposure to tobacco, and prevalence of pulmonary and 
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 Table 2 
 MVA—Independent Predictors or Determinants of Dyspnea 
Variable Unstandardized  β (95% CI) Standardized  β Partial  R 2  P Value 
LC13-Dyspnea a     
 HFrEF (N/Y)  − 15.5 ( − 28.0 to  − 2.97)  − 0.25 0.08 .02 
 Anxiety/depression/PTSD (N/Y)  − 20.8 ( − 32.4 to  − 9.09)  − 0.36 0.15 .001 
 FEV 1 % predicted  − 0.28 ( − 0.49 to  − 0.06)  − 0.27 0.09 .01 
SOBQ b 
 HFrEF (N/Y)  − 15.8 ( − 27.9 to  − 3.63)  − 0.27 0.10 .01 
 Anxiety/depression/PTSD (N/Y)  − 17.0 ( − 29.0 to  − 4.91)  − 0.31 0.12 .01 
 Lung hyperinflation c (N/Y)  − 11.0 ( − 23.3 to 1.21)  − 0.20 0.05 .08 
 FEV 1 % predicted  − 0.34 ( − 0.56 to  − 0.11)  − 0.33 0.13 .004 
 Abbreviations: FEV 1 , forced expiratory volume in the first second of expiration; HFrEF, heart failure with reduced ejection fraction; LC13, European Organization for the Research and Treatment 
of Cancer Quality of Life Questionnaire Lung Cancer Module 13; PTSD, post-traumatic stress disorder; SOBQ, University of California San Diego Shortness of Breath Questionnaire. 
 a Overall model  R  2  = 0.26,  P  < .001; no significant interaction between HFrEF and anxiety/depression/PTSD ( P  = .14) or anxiety/depression/PTSD and FEV 1 % predicted ( P  = .48). 
 b Overall model  R  2  = 0.37,  P  < .001; no significant interaction between HFrEF and anxiety/depression/PTSD ( P  = .15), or anxiety/depression/PTSD and FEV 1 % predicted ( P  = .68). 
 c Data available in 64 participants. 
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cardiovascular comorbidities. 5 The median age at lung cancer 
diagnosis is 70 yr. 34 Most of lung cancer cases are caused by 
cigarette smoking, 35 which has many adverse health conse-
quences. The most common comorbidities in patients with 
lung cancer, all of which can progressively and negatively im-
pact health, are COPD, 36 , 37 diabetes, and heart failure, prev-
alent in 50-70%, 16%, and 13% of patients, respectively. 5 
In addition, the effects of curative-intent therapy of lung 
cancer have unique effects on cardiopulmonary health since 
part of the therapy requires local destruction and/or removal 
of lung tissue, which may exacerbate symptoms and impede 
function and EC in some patients, making typical exercise 
interventions inaccessible. 31 The characterization of dyspnea 
may provide important insights into strategies to effectively 
improve exercise in this group of cancer survivors. 
 The mechanisms of dyspnea are incompletely under-
stood 38 ; however, peripheral sensors including through 
refl ex chemoreceptor stimulation by carbon dioxide, pul-
monary vagal C-fi bers, mechanoreceptors, and central 
pathways (specifi cally the limbic system and sensorimotor 
 Figure 1.  Clinical predictors or determinants of dyspnea. (A) Dyspnea scores as assessed by the LC13 by (i) HFrEF; mean  ± SE difference  = 15.3  ± 
6.91,  P  = .03. (Independent-samples  t tests, equal variances assumed.) (ii) Anxiety/depression/PTSD; mean  ± SE difference  = 19.4  ± 6.30,  P  = 
.003. (Independent-samples  t tests, equal variances assumed.) (iii) FEV 1 % predicted;  R 2 values derived from univariable linear regression analyses 
(UVAs) as listed in Supplemental Digital Content 3, available at:  http://links.lww.com/JCRP/A134 . (B) Dyspnea scores as assessed by the SOBQ by 
(i) HFrEF; mean  ± SE difference  = 16.5  ± 6.69,  P  = .02. (Independent-samples  t tests, equal variances assumed.) (ii) Anxiety/depression/PTSD; 
mean  ± SE difference  = 19.9  ± 6.10,  P  = .002. (Independent-samples  t tests, equal variances assumed.) (iii) FEV 1 % predicted;  R 2 values derived 
from UVAs as listed in Supplemental Digital Content 3, available at:  http://links.lww.com/JCRP/A134 . Abbreviations: FEV 1 , forced expiratory volume 
in the fi rst second of expiration; HFrEF, heart failure with reduced ejection fraction; LC13, European Organization for the Research and Treatment 
of Cancer Quality of Life Questionnaire Lung Cancer Module 13; PTSD, post-traumatic stress disorder; SOBQ, University of California San Diego 
Shortness of Breath Questionnaire. 
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 Table 3 
 Univariable Linear Regression Analysis—Signifi cant/Borderline Predictors of Functional Exercise Capacity 
Variable Unstandardized  β Standardized  β  R 2  P Value 
Age, yr  − 4.58  − 0.31 0.10 .01 
Hyperlipidemia (N/Y) 86.2 0.28 0.08 .02 
CAD (N/Y) 68.5 0.26 0.07 .02 
FEV 1 % predicted 0.96 0.19 0.04 .097 
DL CO % predicted 2.07 0.42 0.18  < .001 
Adenocarcinoma histology (N/Y)  − 82.0  − 0.33 0.11 .004 
Primary treatment group N/A N/A 0.18 .001 
Dyspnea scores, each point 
 LC13  − 1.49  − 0.31 0.10 .01 
 SOBQ  − 1.85  − 0.38 0.15 .001 
 Abbreviations:  β , regression coefficient; CAD, coronary artery disease; DL CO , diffusion capacity of the lung for carbon monoxide; FEV 1 , forced expiratory volume in the first second of 
expiration; LC13, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module 13; SOBQ, University of California San Diego Shortness 
of Breath Questionnaire. 
 Table 4 
 Dyspnea Is an Independent Predictor of Functional Exercise Capacity 
Variable Unstandardized  β (95% CI) Standardized  β Partial  R 2  P Value 
Model 1 a,b (LC13-Dyspnea) 
 Age, yr  − 5.81 ( − 8.54 to  − 3.08)  − 0.39 0.21  < .001 
 Hyperlipidemia (N/Y) 72.0 (15.9-128.0) 0.23 0.09 .01 
 DL CO % predicted 1.81 (0.90-2.73) 0.37 0.18  < .001 
 LC13-Dyspnea, point  − 1.54 ( − 2.43 to  − 0.64)  − 0.32 0.14 .001 
Model 2 b,c (SOBQ) 
 Age, yr  − 5.86 ( − 8.55 to  − 3.16)  − 0.40 0.21  < .001 
 Hyperlipidemia (N/Y) 61.6 (6.62-116.6) 0.20 0.07 .03 
 DL CO % predicted 1.70 (0.79-2.62) 0.35 0.16  < .001 
 SOBQ, point  − 1.70 ( − 2.62 to  − 0.78)  − 0.35 0.16  < .001 
 Abbreviations: DL CO , diffusion capacity of the lung for carbon monoxide; LC13, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 
Module 13; SOBQ, University of California San Diego Shortness of Breath Questionnaire. 
 a Overall  model  R  2  = 0.45,  P  < .001; no significant interaction between age and LC13-Dyspnea ( P  = .40), or DL CO % predicted and LC13-Dyspnea ( P  = .30). 
 b Covariates selected to enter model ( P  < .1): age, hyperlipidemia, coronary artery disease, forced expiratory volume in the first second of expiration (FEV 1 ) % predicted, DL CO % predicted, 
adenocarcinoma, and treatment group ( Table 3 ). 
 c Overall model  R 2  = 0.46,  P  < .001; no significant interaction between age and SOBQ ( P  = .995), or DL CO % predicted and SOBQ ( P  = .55). 
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cortex) are thought to play important roles. 38 In lung can-
cer survivors following curative-intent therapy, dyspnea can 
be made worse due to a loss of 10-15% of lung function 
from lobectomy. 39 In addition, other possible pathophysio-
logical effects may include a loss of associated nerve fi bers 
and peripheral sensors due to the removal and/or destruc-
tion of lung tissue by surgery and/or radiotherapy. Adjuvant 
chemotherapy has been shown to cause peripheral neurop-
athy 40 and, therefore, possibly also vagal perturbations. 
These effects may accumulatively result in neuromechani-
cal dissociation, which is implicated in the pathogenesis of 
dyspnea. 41 
 Importantly, dyspnea was independently associated with 
functional EC in this study. For each 1-point increase in 
baseline dyspnea score, there was a 1.5- to 1.7-m decrease 
in the 6MWD. The association between dyspnea and func-
tional EC has been described in other patient populations 
including COPD. 42 To the best of our knowledge, this re-
lationship has not been previously characterized in lung 
cancer survivors following curative-intent therapy, many 
of whom experience worsening of dyspnea 6 as laid out 
previously. Moreover, a previous analysis of 359 postsur-
gical, stage I NSCLC survivors showed that dyspnea was 
signifi cantly associated with physical health. 10 In fact, of all 
the variables included in that study, 10 dyspnea had approx-
imately twice the effect size ( β ) on physical health as the 
next 2 largest effect sizes (employment status and depres-
sion symptoms). Another study also confi rmed this large 
effect size of dyspnea on physical health. 43 These fi ndings 
suggest that alleviating dyspnea may be a key factor to im-
prove exercise in these patients. 
 The prevalence of abnormally high dyspnea in the cur-
rent study (60%) is similar to previous reports in lung 
cancer survivors following curative-intent therapy. 8-11 In 
1 study, 8 the prevalence of COPD (23%) was signifi cantly 
lower (75%), while the prevalence of abnormal/clinically 
signifi cant dyspnea was the same. In that study, 65% dys-
pneic patients reported not having dyspnea preoperatively, 
suggesting treatment-related effects. 8 Moreover, LC13 dys-
pnea scores were reported to be higher in 830 post-surgical 
lung cancer survivors than in propensity-matched individu-
als from the general population, particularly in those with 
cardiac or pulmonary comorbidity and in those treated 
with combined modality therapy. 44 Results in the current 
study showed an association between treatment type and 
dyspnea scores only in univariable (see Supplemental Dig-
ital Content 3, available at:  http://links.lww.com/JCRP/
A134 ) but not in multivariable ( Table 2 ) analyses, possibly 
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 Figure 2.  Dyspnea is an independent predictor of functional exercise capacity (6MWD). (A) Dyspnea as assessed by the LC13. (B) Dyspnea as 
assessed by the SOBQ,  R 2 values derived from univariable linear regression analyses as listed in  Table 3 . LC13, European Organization for the 
Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module 13; 6MWD, 6-minute walk distance; SOBQ, University of 
California San Diego Shortness of Breath Questionnaire. 
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due to a small sample size and/or inclusion of lung function. 
The predictors or determinants of dyspnea identifi ed offer 
complimentary information to a previous report in 342 
post-surgical NSCLC survivors 8 and another in 142 long-
term, post-surgical NSCLC survivors. 43 In addition, HFrEF 
and psychiatric illness were identifi ed as predictors or de-
terminants, which have clinical management implications 
in these patients. 
 This study has novel insights. Historically, most lung 
cancer cases were diagnosed at advanced stages and treat-
ed with palliation. However, the landscape for lung cancer 
is changing rapidly 45 due to advances in screening, 46 , 47 di-
agnostic, 48 and therapeutic 49 , 50 modalities. As the number 
of earlier-stage lung cancer survivors increases, 51 , 52 more 
attention must be paid to the unique health challenges 
faced by this group of cancer survivors. 12 A prospective 
study was recently completed which showed that dyspnea 
symptoms worsen at 1 to 3 mo following curative-intent 
lung cancer treatment. 53 As such, it is postulated that in 
order to maximize efforts to improve exercise, function, 
and QoL in lung cancer survivors following curative-intent 
treatment, optimizing medical therapy for cardiopulmonary 
disease 54 and possibly psychiatric illness 55 to alleviate dys-
pnea may also be important. Recent randomized controlled 
trials in patients with COPD have shown that combination 
long-acting muscarinic-antagonist and  β -agonist inhaler 
therapy is effective in reducing dyspnea 56 and, possibly, in 
improving physical activity. 57 , 58 Initiation of combination 
long-acting muscarinic-antagonist and  β -agonist broncho-
dilators, particularly in survivors with concomitant COPD, 
may be an important fi rst step. Moreover, while exercise 
training as part of comprehensive rehabilitation programs 
may improve function and QoL in lung cancer survivors, 
studies in patients with chronic lung disease show that the 
benefi ts of exercise training wane over time, as patients do 
not increase or maintain activity outside the training set-
ting. 59 A recent systematic review of exercise programs in 
lung cancer survivors identifi ed the need for home-based 
exercise programs, 31 reported by many cancer survivors to 
be more desirable. 60 In addition, traditional exercise inter-
ventions focus on moderate to vigorous intensity exercise. 
More recently, light-intensity exercise and sedentary behav-
ior are also recognized as important in health promotion: 
the US Department of Health & Human Services empha-
sized that moving more and sitting less will benefi t near-
ly everyone. 61 Therefore, in addition to reducing dyspnea, 
exercise interventions in lung cancer survivors may need to 
also promote light-intensity exercise and reduce sedentary 
behavior to be effective (see Supplemental Digital Content 
1, available at:  http://links.lww.com/JCRP/A132 ). 
 This study has limitations. First, despite a thorough list 
of important clinical characteristics in the lung cancer pop-
ulation, only 30-40% of the variances in dyspnea scores 
were explained. However, to the best of our knowledge, no 
other studies have reported higher  R 2 values including those 
reported in a large, international, population-based study 
involving 9484 participants with many demographic and 
clinical variables (largest  R 2 reported  = 0.13). 62 Second, the 
cross-sectional and descriptive nature of this study provides 
no insight on the effects of lung cancer treatment on dys-
pnea, the underlying physiobiological mechanism, or how 
to effectively alleviate it; information on medical therapy for 
comorbidities was not collected, limiting the ability to draw 
conclusions between medical therapy and dyspnea scores. 
Third, these fi ndings may have limited generalizability due 
to it being a single-institutional study involving a predom-
inantly white male veteran patient population with signifi -
cant tobacco exposure and higher prevalence of COPD and 
psychiatric illness. 5 Fourth, lung function (FEV 1 ) but not a 
spirometric diagnosis of COPD was associated with dys-
pnea in this study, which may be due to the small sample 
size and/or a limitation in data containing both pre- and 
post-treatment lung function. Fifth, in this study, 35% of 
lung cancer survivors had coronary artery disease, 40% had 
previous history of other cancers, and 79% of those who 
had undergone echocardiography had diastolic dysfunc-
tion, all of which could additionally impact dyspnea. These 
variables were not signifi cantly associated with dyspnea, 
possibly due to a small sample size. 
 The strengths of this study include a detailed list of 
comorbidities and physiological measures of cardiopul-
monary health including lung function, all of which were 
entered in the electronic medical record and collected by 
board-certifi ed physicians, maximizing the accuracy of the 
data obtained. In addition, all patient reported outcome  and 
functional EC assessments were performed in-person by 1 
observer (D.H.), maximizing the completeness and accuracy 
of the data collected and minimizing interobserver variabili-
ty. Finally, the fi ndings were verifi ed using a second dyspnea 
questionnaire, maximizing the validity of the conclusions. 
 In conclusion, abnormally high dyspnea was prevalent 
in  ≥ 50% of lung cancer survivors following curative-in-
tent therapy, partly due to underlying psychiatric illness, 
presence of HFrEF, and obstructive ventilatory defects. In 
addition, dyspnea was a signifi cant independent predictor 
of functional EC. Efforts to improve exercise, function, 
and QoL in lung cancer survivors may need to also fo-
cus on optimizing therapy for comorbid cardiopulmonary 
and/or psychiatric illnesses and reduce dyspnea to be ef-
fective. 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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